title: CCL2 DNA vaccine to treat renal disease.
abstract: CCL2 DNA vaccines are directed against the host chemoattractant molecule CCL2 (MCP-1), a key chemokine in recruiting macrophages to sites of inflammation. Macrophages recruited by CCL2 lead to progressive renal injury. In rat models of disease unmodified CCL2 DNA vaccine in combination with a CCL5 (RANTES) DNA vaccine can protect against chronic renal disease. The mechanism of protection involves the induction of auto-antibodies to the CCL2. Introduction of the adjuvant p-tet into the DNA structure of the CCL2 vaccine leads to enhanced potency with the induction of specific Th1 cellular immunity. The strategies outlined here demonstrate a model for developing potent vaccines against highly restricted self targets.
authors.affiliation: Centre for Kidney Research, Children's Hospital at Westmead, Westmead, New South Wales, Australia.
authors.forename: Debbie
authors.initials: D
authors.lastname: Watson
authors.forename: Guoping
authors.initials: G
authors.lastname: Zheng
authors.forename: Huiling
authors.initials: H
authors.lastname: Wu
authors.forename: Yuan Min
authors.initials: YM
authors.lastname: Wang
authors.forename: Yiping
authors.initials: Y
authors.lastname: Wang
authors.forename: David C H
authors.initials: DC
authors.lastname: Harris
authors.forename: S I
authors.initials: SI
authors.lastname: Alexander